While more than two dozen pharmaceutical firms are in a race to develop the first effective vaccine against the coronavirus, CureVac may have an edge thanks to an experimental technology that allows it to deliver the prophylactic in extremely small doses.

It appears to have caught Mr Trump’s eye when he met the company’s chief executive during a crisis summit